Opioid Use Disorder Market Insights and Future Trends 2024-2032
As per industry estimates, the Opioid Use Disorder Market was valued at USD 3.06 billion in 2022 and is expected to reach USD 5.65 billion by 2030, growing at a CAGR of 8.1% during the forecast period. The Opioid Use Disorder Market Size is becoming increasingly relevant due to rising incidence rates and growing global emphasis on effective treatment protocols.
The market is being propelled by a surge in opioid addiction cases, increasing healthcare initiatives, and advancements in therapeutic approaches. Government-led awareness programs, combined with the availability of medication-assisted treatment (MAT), are helping reduce the stigma surrounding the disorder, encouraging more patients to seek medical help. Innovation in treatment therapies, especially the development of long-acting formulations and abuse-deterrent drugs, is also reshaping the market landscape.
Get Free Sample Report @ https://www.snsinsider.com/sample-request/3018
Key Players
- Indivior PLC (Sublocade, Suboxone)
- Alkermes plc (Vivitrol, Aristada)
- Purdue Pharma L.P. (Hysingla ER, Butrans)
- Braeburn Pharmaceuticals (Brixadi, Probuphine)
- BioDelivery Sciences International, Inc. (Belbuca, Bunavail)
- Titan Pharmaceuticals, Inc. (Probuphine Implant, ProNeura)
- Teva Pharmaceutical Industries Ltd. (Buprenorphine, Naloxone Tablets)
- Camurus AB (Buvidal, Episil Oral Liquid)
- Mallinckrodt Pharmaceuticals (Methadose, Roxicodone)
- Orexo AB (Zubsolv, Abstral)
Key Points:
- Market size expected to grow from USD 3.06 billion (2022) to USD 5.65 billion (2030)
- CAGR of 8.1% projected during the forecast period (2023–2030)
- Rising adoption of MAT (Medication-Assisted Treatment) methods
- Increased focus on reducing opioid overdose deaths globally
- Growth driven by awareness campaigns and healthcare accessibility
- Technological innovation in long-acting therapies and drug delivery
- North America leads market share due to supportive policies and high prevalence
Future Scope:
With ongoing research and the development of more targeted and safer therapeutic solutions, the opioid use disorder market is expected to evolve significantly. The future holds promise for AI-driven diagnostic tools, personalized treatment plans, and digital therapeutics integration, particularly in remote or underserved regions. In addition, global collaborations between pharmaceutical companies and public health bodies are poised to accelerate innovation and treatment delivery on a larger scale.
Conclusion:
The Opioid Use Disorder Market Size reflects a strong upward trajectory fueled by medical advancements, policy reforms, and heightened public awareness. As the healthcare ecosystem continues to address opioid misuse with holistic strategies, the market is likely to witness sustainable and impactful growth in the years to come.
Contact Us:
Jagney Dave - Vice President of Client Engagement
Phone: +1-315 636 4242 (US) | +44- 20 3290 5010 (UK)
Other Related Reports:
Comments
0 comment